Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc.
47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 517
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 1.44M | 1.31M | 1976 |
| Ms. Samantha Prout | Chief Accounting Officer & Controller | N/D | N/D | 1978 |
| Dr. Jill Weimer Ph.D. | Chief Science Officer | N/D | N/D | N/D |
| Andrew Faughnan | Senior Director of Investor Relations | N/D | N/D | N/D |
| Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | N/D | N/D | N/D |
| Ms. Diana Moore | Head of Global Corporate Communications | N/D | N/D | N/D |
| Ms. Jayne C. Gershkowitz | Chief Patient Advocate | N/D | N/D | 1957 |
| Ms. Julie Yu | Chief Program Officer | N/D | N/D | 1967 |
| Mr. Anthony Sileno | Senior Vice President of Clinical Operations & Translational Sciences | N/D | N/D | N/D |
| Mr. Simon Jordan | Chief Global Head of Rare Diseases | N/D | N/D | N/D |
Descripción
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Amicus Therapeutics, Inc. a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 8; Junta: 3; Derechos del accionista: 7; Compensación: 5.
